Semaglutide Side Effects and Depression: Sorting Fact from Uncertainty

Is depression officially a side effect of Wegovy?

Looking at the UK prescribing information for semaglutide (Wegovy), depression does not appear in the list of common, uncommon or rare adverse reactions. The NHS medicines page for semaglutide describes the well-documented side effects as primarily gastrointestinal: nausea, vomiting, diarrhoea, constipation and indigestion are the ones most people encounter, typically in the first few weeks or after a dose step. Fatigue, headache and dizziness also feature. Mood disturbance is not part of that established picture, and you can explore what side effects from semaglutide have been reported more broadly if you want a fuller picture of how people respond to the medicine.

In the pivotal STEP 1 trial, which followed nearly 2,000 adults over 68 weeks, depression rates did not differ significantly between the semaglutide and placebo groups. Regulators in the UK and Europe reviewed these data before licensing. So the short answer to whether Wegovy causes depression is: there is currently no good clinical-trial evidence that it does.

That does not mean every person's experience will be neutral. Anecdotal reports of low mood, emotional flatness or changes in motivation do appear in patient communities, and the MHRA continues to monitor all post-market safety signals, including those related to neuropsychiatric effects. If the evidence shifts, guidance will be updated, which is precisely why Yellow Card reporting matters.

What might be driving mood changes if not the drug itself?

This is the part of the question that deserves honest attention. Starting a GLP-1 medicine is not a small thing physiologically. Appetite drops sharply. Food, which many people use as comfort or social glue, suddenly feels less compelling. Some people describe a loss of pleasure in eating that feels unsettling, even when they are objectively making progress. Weight loss itself, particularly rapid loss, can temporarily disrupt hormone levels, sleep patterns and energy, all of which influence mood.

There is also the psychological dimension. People who have spent years struggling with weight often carry complex feelings about their body, food and self-worth. Treatment can surface those feelings, sometimes unexpectedly. This is not a side effect of semaglutide; it is part of navigating a significant life change. Our dedicated page on Wegovy and depression and anxiety explores the psychological context in more depth, which is worth reading before drawing conclusions either way.

The practical upshot: if your mood dips during treatment, it is worth identifying whether the timing correlates with dose changes, disrupted sleep, eating less than your body needs, or a reduction in activity, before assuming the medicine is the cause. Understanding how long semaglutide side effects last can also help you judge whether what you are experiencing is likely to settle with time.

When to get medical help, and who to call

The threshold for contacting a clinician should be low. If you notice persistent low mood lasting more than a week or two, a loss of interest in things that usually matter to you, feelings of hopelessness, or any thoughts of self-harm, speak to your GP or contact a clinician the same day. These symptoms need proper assessment regardless of what is causing them, and continuing a weight-loss medicine while your mental health is deteriorating is not the right call without clinical input.

Our prescribers are available seven days a week for aftercare queries, you do not need to wait until your next order. If something feels wrong, get in touch with us directly. For urgent mental health support, NHS 111 is available around the clock, and the Samaritans can be reached on 116 123 at any time.

Separately, if you experience any side effect that concerns you, report it via the MHRA Yellow Card scheme. The scheme exists precisely to capture signals that post-marketing surveillance might otherwise miss, including neuropsychiatric effects that were not prominent in pre-licensing trials.

What this means for your decision about starting semaglutide

The evidence base does not support framing depression as a predictable consequence of taking Wegovy. For the majority of people in the clinical trials, mood was not adversely affected. Some found that improving their weight and health had a positive effect on how they felt about themselves, weight and mental health are connected in both directions.

What the evidence does support is taking your mental health into account when starting any new treatment. If you have a history of depression, the conversation with your prescriber at consultation is the right time to raise it, not as a disqualifier, but as relevant context that shapes how treatment is managed. You can read a full overview of semaglutide's side-effect profile to understand the broader picture, and our page covering each side effect of semaglutide in detail is a useful companion if you want to look at individual reactions more closely, and our Wegovy information page covers what the medicine is licensed for, how it works and what to expect across the course of treatment.

Starting treatment is a clinical decision, and our prescribers discuss side effects, your history and your suitability as part of the consultation process, not as a box-tick, but as a genuine clinical conversation. Check your eligibility to get started.